Patents by Inventor Praveen Kumar Subbappa
Praveen Kumar Subbappa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122858Abstract: Modified-release pharmaceutical compositions of ruxolitinib or a pharmaceutically acceptable salt thereof are disclosed. Preferably, the invention relates to oral modified-release pharmaceutical compositions of ruxolitinib, which enable once-daily administration. Oral modified-release compositions of ruxolitinib, methods for their administration, processes for their preparation, and use of these compositions for treatment of diseases treatable by ruxolitinib are also described.Type: ApplicationFiled: December 7, 2023Publication date: April 18, 2024Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Krishna Mohan LAKSHMIPATHULA, Somnath Devidas NAVGIRE, Hanimi Reddy BAPATU, Sandeep JAIN, Sumitra Ashokkumar PILLAI, Praveen Kumar SUBBAPPA
-
Publication number: 20240050416Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.Type: ApplicationFiled: July 24, 2023Publication date: February 15, 2024Applicant: Slayback Pharma LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
-
Publication number: 20230381282Abstract: Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.Type: ApplicationFiled: May 25, 2023Publication date: November 30, 2023Applicant: Slayback Pharma LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230301945Abstract: The present invention relates to stable oral pharmaceutical compositions in the form of a solution comprising: hydroxyurea at a concentration of about 10 mg/mL to about 500 mg/mL; at least one pharmaceutically acceptable liquid vehicle; and one or more amino acids selected from the group consisting of glycine, alanine, glutamic acid, L-arginine, lysine, L-cysteine, methionine and mixtures thereof, wherein the level of carbamoyloxyurea in the solution is less than 0.5 % w/w as measured by HPLC when the solution is stored at 25° C./60% RH for at least 3 months. The invention further relates to processes for the production of the compositions, methods for their administration, and their use for treatment of diseases treatable by hydroxyurea.Type: ApplicationFiled: February 2, 2023Publication date: September 28, 2023Applicant: Slayback Pharma LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian ., Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230285368Abstract: Liquid pharmaceutical compositions of apixaban or pharmaceutically acceptable salts thereof are described. More specifically, stable oral liquid pharmaceutical compositions of apixaban for oral administration are provided, wherein the composition is stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of apixaban at concentrations of 0.4 mg/mL or more are provided. Stable oral liquid compositions of apixaban, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by apixaban are disclosed.Type: ApplicationFiled: March 6, 2023Publication date: September 14, 2023Applicant: Slayback Pharma LLCInventors: Sushant Omprakash Dube, Girish G. Kore, Naga Venkata Durga Prasad Ketha, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230248742Abstract: Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: ApplicationFiled: April 12, 2023Publication date: August 10, 2023Applicant: SLAYBACK PHARMA LLCInventors: Umangi K. SONI, Prem Prakash SINGH, Hanimi Reddy BAPATU, Praveen Kumar SUBBAPPA, Ajay Kumar SINGH
-
Publication number: 20230190737Abstract: The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising: (a) netupitant and optionally palonosetron; (b) at least one pharmaceutically acceptable stabilizer; (c) at least one pharmaceutically acceptable solubilizer; and (d) at least one pharmaceutically acceptable vehicle, wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6. The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.Type: ApplicationFiled: December 20, 2022Publication date: June 22, 2023Applicant: Slayback Pharma LLCInventors: Ashish Anilrao Dubewar, Rahul Dhulaji Bhise, Mahadeo Vasant Mahadik, Shanker Mamidi, Mayur Anshiram Adhav, Raghavender Rao Kategher, Nagaraj Gangam, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230172863Abstract: The present invention relates to modified-release pharmaceutical compositions of ruxolitinib or its pharmaceutically acceptable salts thereof. Preferably, the invention relates to oral modified-release pharmaceutical compositions of ruxolitinib, which enable once-daily administration. The present invention further relates to oral modified-release compositions of ruxolitinib, methods for their administration, processes for their preparation, and use of these compositions for treatment of diseases treatable by ruxolitinib.Type: ApplicationFiled: December 5, 2022Publication date: June 8, 2023Inventors: Paras P. JAIN, Krishna Mohan LAKSHMIPATHULA, Somnath Devidas NAVGIRE, Hanimi Reddy BAPATU, Sandeep Jain, Sumitra Ashokkumar PILLAI, Praveen Kumar SUBBAPPA
-
Patent number: 11642355Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: GrantFiled: March 16, 2022Date of Patent: May 9, 2023Assignee: SLAYBACK PHARMA LLCInventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
-
Publication number: 20220202830Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: ApplicationFiled: March 16, 2022Publication date: June 30, 2022Applicant: SLAYBACK PHARMA LLCInventors: Umangi K. SONI, Prem Prakash SINGH, Hanimi Reddy BAPATU, Praveen Kumar SUBBAPPA, Ajay Kumar SINGH
-
Patent number: 11311554Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: GrantFiled: March 25, 2019Date of Patent: April 26, 2022Assignee: SLAYBACK PHARMA LLCInventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
-
Patent number: 11103502Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 27, 2019Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Patent number: 11103503Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: January 28, 2020Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20200222395Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: January 28, 2020Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Praveen Kumar SUBBAPPA, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Hanimi Reddy BAPATU, Sandeep JAIN
-
Publication number: 20200222394Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 27, 2019Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20190307772Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: ApplicationFiled: March 25, 2019Publication date: October 10, 2019Applicant: SLAYBACK PHARMA LLCInventors: Umangi K. SONI, Prem Prakash SINGH, Hanimi Reddy BAPATU, Praveen Kumar SUBBAPPA, Ajay Kumar SINGH
-
Patent number: 7199111Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.Type: GrantFiled: December 2, 2003Date of Patent: April 3, 2007Assignee: Bharat Serums & Vaccines Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Praveen Kumar Subbappa
-
Publication number: 20040186074Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.Type: ApplicationFiled: December 2, 2003Publication date: September 23, 2004Applicant: Bharats Serums & Vaccines LTd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Praveen Kumar Subbappa